JP2003533479A - カンナビノイド薬剤 - Google Patents

カンナビノイド薬剤

Info

Publication number
JP2003533479A
JP2003533479A JP2001583765A JP2001583765A JP2003533479A JP 2003533479 A JP2003533479 A JP 2003533479A JP 2001583765 A JP2001583765 A JP 2001583765A JP 2001583765 A JP2001583765 A JP 2001583765A JP 2003533479 A JP2003533479 A JP 2003533479A
Authority
JP
Japan
Prior art keywords
cells
acid
thc
cell proliferation
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001583765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533479A5 (enExample
Inventor
バースタイン サムナー
レヒト ローレンス
ビー．ズーリア ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2003533479A publication Critical patent/JP2003533479A/ja
Publication of JP2003533479A5 publication Critical patent/JP2003533479A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
JP2001583765A 2000-05-17 2001-05-17 カンナビノイド薬剤 Pending JP2003533479A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
US60/204,935 2000-05-17
PCT/US2001/016150 WO2001087297A1 (en) 2000-05-17 2001-05-17 Cannabinoid drugs

Publications (2)

Publication Number Publication Date
JP2003533479A true JP2003533479A (ja) 2003-11-11
JP2003533479A5 JP2003533479A5 (enExample) 2008-07-10

Family

ID=22760084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001583765A Pending JP2003533479A (ja) 2000-05-17 2001-05-17 カンナビノイド薬剤
JP2001583763A Pending JP2003533478A (ja) 2000-05-17 2001-05-17 （３ｒ，４ｒ）−δ８−テトラヒドロカンナビノール−１１−酸に基づく細胞増殖の低減方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2001583763A Pending JP2003533478A (ja) 2000-05-17 2001-05-17 （３ｒ，４ｒ）−δ８−テトラヒドロカンナビノール−１１−酸に基づく細胞増殖の低減方法

Country Status (13)

Country Link
US (2) US6448288B1 (enExample)
EP (2) EP1307188B1 (enExample)
JP (2) JP2003533479A (enExample)
CN (2) CN1273123C (enExample)
AT (1) ATE406156T1 (enExample)
AU (5) AU6169501A (enExample)
CA (2) CA2409005A1 (enExample)
DE (1) DE60135557D1 (enExample)
HU (2) HUP0700039A2 (enExample)
IL (3) IL152892A0 (enExample)
NZ (2) NZ523029A (enExample)
RU (2) RU2272620C2 (enExample)
WO (3) WO2001087297A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487436A4 (en) 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
DE60320784D1 (de) * 2002-06-06 2008-06-19 Yissum Res Dev Co Stände zur modulierung des knochenwachstums
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
EP1633733B1 (en) * 2003-05-20 2011-01-26 The University of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US20060128738A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
WO2006065793A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
AU2006297300B2 (en) * 2005-09-29 2012-05-10 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US20070093519A1 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
WO2007055806A1 (en) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
WO2009071687A1 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8546401B2 (en) 2007-12-07 2013-10-01 AbbVie Deutschland GmbH & Co. KG 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
BRPI0820668A2 (pt) 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
JP2020529421A (ja) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
CN111233814A (zh) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 一种萜酚类化合物zkyy-057及其制备方法和应用
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020268A1 (en) * 1997-10-17 1999-04-29 Atlantic Pharmaceuticals, Inc. (3r,4r)-δ-tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (es) * 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020268A1 (en) * 1997-10-17 1999-04-29 Atlantic Pharmaceuticals, Inc. (3r,4r)-δ-tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics

Also Published As

Publication number Publication date
CN1452485A (zh) 2003-10-29
CN1273123C (zh) 2006-09-06
WO2001087295A8 (en) 2003-04-10
AU6169501A (en) 2001-11-26
EP1307188A4 (en) 2005-07-06
WO2001087296A1 (en) 2001-11-22
US20040225011A1 (en) 2004-11-11
WO2001087297A1 (en) 2001-11-22
IL152892A0 (en) 2003-06-24
DE60135557D1 (de) 2008-10-09
AU2001261695B2 (en) 2005-06-16
US6448288B1 (en) 2002-09-10
IL152891A0 (en) 2003-06-24
HUP0700039A2 (en) 2007-05-02
AU2001263217A1 (en) 2001-11-26
EP1307186A1 (en) 2003-05-07
CA2409005A1 (en) 2001-11-22
US20020022653A1 (en) 2002-02-21
AU6468001A (en) 2001-11-26
CA2408961A1 (en) 2001-11-22
NZ523028A (en) 2004-09-24
RU2273476C2 (ru) 2006-04-10
ATE406156T1 (de) 2008-09-15
NZ523029A (en) 2004-11-26
JP2003533478A (ja) 2003-11-11
EP1307186A4 (en) 2005-10-19
HUP0700038A2 (en) 2007-05-02
US6914072B2 (en) 2005-07-05
AU2001264680B2 (en) 2006-09-14
CN1447685A (zh) 2003-10-08
CN1227007C (zh) 2005-11-16
WO2001087295A1 (en) 2001-11-22
EP1307188B1 (en) 2008-08-27
RU2272620C2 (ru) 2006-03-27
EP1307188A1 (en) 2003-05-07
IL152892A (en) 2010-06-30

Similar Documents

Publication Publication Date Title
JP2003533479A (ja) カンナビノイド薬剤
AU2001264680A1 (en) Cannabinoid drugs
AU2001261695A1 (en) Methods for decreasing cell proliferation based on (3R, 4R)-delta8-tetrahydrocannabinol-11-oic acids
AU766988B2 (en) Cannabinoids as antioxidants and neuroprotectants
AU632330B2 (en) Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
US4910224A (en) Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein
US6974835B2 (en) Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
US6358997B1 (en) Tocopherol and tocotrienol compositions
AU604226B2 (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein
US20060128794A1 (en) Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids
US20020061924A1 (en) Agent containing tocotrienol for drug
CA2611860A1 (en) Compositions and methods of use of derivatized flavanols
Axelrod et al. I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
JPH03504509A (ja) 治療に有用な血小板抗凝集効果を有する新しい組成物

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040818

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018